SPASTICITY-DANTROLENE

SUMMARY

1. Peripheral site of action, reduces extrafusal & intrafusal muscle fiber activity by blocking the release of Ca²⁺ from the sarcoplasmic reticulum.

2. The only medication that does not affect CNS.

3. Dosage: 25-400mg/day.

4. Preferred for spasticity due to TBI, stroke, CP. Also used for malignant hyperthermia, neuroleptic malignant syndrome, Baclofen-withdrawal.

5. Adverse effects: hepatotoxicity, sedation, weakness, fatigue, paraesthesia, GIT effects.

Reference(s)

Cifu, D.X. (2020). Braddom’s physical medicine and rehabilitation. Elsevier. Get it on Amazon.
Cuccurullo, S. (2019). Physical medicine and rehabilitation board review. New York: Demosmedical. Get it on Amazon.
O’Young, B., Young, M.A. and Stiens, S.A. (2008). Physical Medicine and Rehabilitation Secrets. Mosby. Get it on Amazon.